EUVIMEDObjevte EUVIMED
Open access · CC BY 4.0

Suppression of Retinal Neovascularisation by Tetrahedral Framework Nucleic Acids‐Resveratrol Via Dual Anti‐Angiogenesis and Anti‐Inflammation

Yili Jin, Tao Cai, Junyang Huang, Li Chen, Yi Lin, Jingying Liu, You Wang, Xiaoyan Ding iD

Cell Proliferation · 2026

DOI: 10.1111/cpr.70227 ↗

At a glance

Journal article in Cell Proliferation, 2026. Written by Yili Jin and 7 co-authors. Institution: Department of Ophthalmology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China. Major MEDLINE topics: Resveratrol, Retinal Neovascularization, Angiogenesis Inhibitors, Anti-Inflammatory Agents. Cited 1 times so far (Crossref); 35 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Retinal neovascular diseases, such as retinopathy of prematurity and diabetic retinopathy, threaten vision by disrupting retinal structure and function through pathological neovascularisation and chronic inflammation. Existing anti‐VEGF therapies primarily target angiogenesis, offering limited control over inflammation and requiring repeated administration. Here, we developed a resveratrol (RSV)‐loaded tetrahedral framework nucleic acid nanostructure (tFNAs‐RSV) to achieve concurrent anti‐angiogenic and anti‐inflammatory effects. tFNAs provided a biocompatible, stable and penetration‐efficient carrier that enhanced RSV ocular delivery and bioactivity. In hypoxia‐induced retinal neovascularisation models, tFNAs‐RSV markedly reduced neovascular lesion area, vascular leakage and retinal inflammatory cell infiltration. Mechanistically, tFNAs‐RSV suppressed HIF‐1 signalling and inhibited the p38 MAPK pathway and NF‐κB p65 pathway. Collectively, these results validate tFNAs‐RSV as a promising nanoplatform for treating retinal neovascular diseases, with an emphasis on inhibiting neovascularisation and inflammation.

Subjects

MeSH terms (MEDLINE)

ResveratrolRetinal NeovascularizationAngiogenesis InhibitorsAnti-Inflammatory AgentsAnimalsMiceHumansDNA NanostructuresVascular Endothelial Growth Factor AInflammationp38 Mitogen-Activated Protein KinasesMice, Inbred C57BLSignal Transduction

Author keywords

MAPK pathwayanti‐angiogenesisanti‐inflammationresveratrolretinal neurovascular unittetrahedral framework nucleic acids

Substances

ResveratrolAngiogenesis InhibitorsAnti-Inflammatory AgentsVascular Endothelial Growth Factor Ap38 Mitogen-Activated Protein Kinases

Authors and institutions

  • Department of Ophthalmology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Sichuan Eye Medical Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
  • Sichuan Eye Medical Center, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
  • The First School of Clinical Medicine, Southern Medical University, Guangzhou, China.
  • Department of Ophthalmology, General Hospital of Central Theater Command, Wuhan, China.

ORCID profiles: Xiaoyan Ding

Funding

  • National Natural Science Foundation of China

Cite

APA

Jin, Y., Cai, T., Huang, J., Chen, L., Lin, Y., Liu, J., Wang, Y., & Ding, X. (2026). Suppression of Retinal Neovascularisation by Tetrahedral Framework Nucleic Acids‐Resveratrol Via Dual Anti‐Angiogenesis and Anti‐Inflammation. Cell Proliferation. https://doi.org/10.1111/cpr.70227

Vancouver

Jin Y, Cai T, Huang J, Chen L, Lin Y, Liu J, et al. Suppression of Retinal Neovascularisation by Tetrahedral Framework Nucleic Acids‐Resveratrol Via Dual Anti‐Angiogenesis and Anti‐Inflammation. Cell Proliferation. 2026. doi:10.1111/cpr.70227

BibTeX
@article{Jin2026,
  author = {Jin, Yili and Cai, Tao and Huang, Junyang and Chen, Li and Lin, Yi and Liu, Jingying and Wang, You and Ding, Xiaoyan},
  title = {Suppression of Retinal Neovascularisation by Tetrahedral Framework Nucleic Acids‐Resveratrol Via Dual Anti‐Angiogenesis and Anti‐Inflammation},
  journal = {Cell Proliferation},
  year = {2026},
  doi = {10.1111/cpr.70227}
}
Start for free →